{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:00:09Z","timestamp":1793829609936,"version":"4.6.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Androgen receptor signaling inhibitors (ARSI) and docetaxel (DTX) are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, the differences in therapeutic efficacy between these treatments for mCRPC after upfront ARSI for metastatic castration-sensitive prostate cancer (mCSPC) remain unclear. In this study, we used real-world data to compare treatment efficacy and to identify prognostic indicators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 120 patients who progressed to mCRPC after receiving ARSI as a first-line therapy for mCSPC. Second-line progression-free survival (PFS) and second-line overall survival (OS) were compared between the DTX and non-DTX groups. Cox proportional hazards regression analysis was performed to identify the prognostic indicators of second-line OS in patients with mCRPC. Propensity score matching was used to adjust for differences in baseline clinical characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among matched patients with mCRPC, no significant differences were observed in second-line PFS or OS between the non-DTX and DTX groups. Univariate and multivariate analyses demonstrated that pretreatment serum lactate dehydrogenase (LDH) levels (&amp;lt;220 vs. \u2265220\u00a0U\/l) and Gleason pattern 5 (GP5) status were significant prognostic indicators for second-line OS in patients with mCRPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pretreatment LDH levels and GP5 status may be useful prognostic indicators for patients with mCRPC following upfront ARSI therapy for mCSPC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag107","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:39:28Z","timestamp":1781613568000},"page":"1248-1254","source":"Crossref","is-referenced-by-count":1,"title":["Screening for prognostic indicators in patients with metastatic castration-resistant prostate cancer after androgen receptor signaling inhibitor treatment for metastatic castration-sensitive prostate cancer"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7505-9608","authenticated-orcid":false,"given":"Keita","family":"Hayakawa","sequence":"first","affiliation":[{"name":"Department of Urology, Kyoto Prefectural University of Medicine , Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto-City, Kyoto 602-8566 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyoto Prefectural University of Medicine , Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto-City, Kyoto 602-8566 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Gabata","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyoto Prefectural University of Medicine , Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto-City, Kyoto 602-8566 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Murashita","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyoto Prefectural University of Medicine , Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto-City, Kyoto 602-8566 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyoto Prefectural University of Medicine , Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto-City, Kyoto 602-8566 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyoto Prefectural University of Medicine , Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto-City, Kyoto 602-8566 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Miyashita","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyoto Prefectural University of Medicine , Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto-City, Kyoto 602-8566 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Shiraishi","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyoto Prefectural University of Medicine , Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto-City, Kyoto 602-8566 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Fujihara","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyoto Prefectural University of Medicine , Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto-City, Kyoto 602-8566 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Okumi","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyoto Prefectural University of Medicine , Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto-City, Kyoto 602-8566 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiya","family":"Hongo","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyoto Prefectural University of Medicine , Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto-City, Kyoto 602-8566 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Ukimura","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyoto Prefectural University of Medicine , Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto-City, Kyoto 602-8566 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"2026100809070446700_ref1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"2026100809070446700_ref2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"2026100809070446700_ref3","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026100809070446700_ref4"},{"key":"2026100809070446700_ref5","doi-asserted-by":"crossref","first-page":"252 e19","DOI":"10.1016\/j.urolonc.2023.03.013","article-title":"Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: a retrospective cohort study","volume":"41","author":"Lowentritt","year":"2023","journal-title":"Urol Oncol"},{"key":"2026100809070446700_ref6","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","article-title":"First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026100809070446700_ref7","doi-asserted-by":"crossref","first-page":"402","DOI":"10.4103\/aja20242","article-title":"Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer","volume":"26","author":"Wang","year":"2024","journal-title":"Asian J Androl"},{"key":"2026100809070446700_ref8","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1007\/s10147-024-02637-6","article-title":"Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor","volume":"29","author":"Yamamoto","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"2026100809070446700_ref9","doi-asserted-by":"crossref","first-page":"10094","DOI":"10.1038\/s41598-021-89609-2","article-title":"Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer","volume":"11","author":"Ueda","year":"2021","journal-title":"Sci Rep"},{"key":"2026100809070446700_ref10","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1007\/s00345-022-04200-2","article-title":"Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients","volume":"40","author":"Ueda","year":"2022","journal-title":"World J Urol"},{"key":"2026100809070446700_ref11","doi-asserted-by":"crossref","DOI":"10.1002\/pros.24855","article-title":"Screening for predictive factors of efficacy of second-generation androgen receptor axis-targeted agents in patients with high-risk metastatic hormone-sensitive prostate cancer","volume":"85","author":"Ueda","year":"2025","journal-title":"Prostate."},{"key":"2026100809070446700_ref12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.eururo.2017.07.035","article-title":"Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for &gt;\/=24 weeks in Europe","volume":"74","author":"Bono","year":"2018","journal-title":"Eur Urol"},{"key":"2026100809070446700_ref13","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026100809070446700_ref14","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1158\/1078-0432.CCR-21-1625","article-title":"Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition","volume":"27","author":"Annala","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026100809070446700_ref15","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"Wit","year":"2019","journal-title":"N Engl J Med"},{"key":"2026100809070446700_ref16","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","article-title":"Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026100809070446700_ref17","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"2026100809070446700_ref18","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.annonc.2025.05.011","article-title":"Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial","volume":"36","author":"Tombal","year":"2025","journal-title":"Ann Oncol"},{"key":"2026100809070446700_ref19","first-page":"3","article-title":"Molecular characterization and clinical outcomes of primary Gleason pattern 5 prostate cancer after radical prostatectomy","author":"Velho","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"2026100809070446700_ref20","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.1002\/cam4.3108","article-title":"Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: a meta-analysis","volume":"9","author":"Li","year":"2020","journal-title":"Cancer Med"},{"key":"2026100809070446700_ref21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/pros.24802","article-title":"Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy","volume":"85","author":"Narita","year":"2025","journal-title":"Prostate."},{"key":"2026100809070446700_ref22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-44627-w","article-title":"Triplet versus doublet therapy in patients with metastatic hormone-sensitive prostate cancer","volume":"16","author":"Hayakawa","year":"2026","journal-title":"Sci Rep"},{"key":"2026100809070446700_ref23","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2217\/fon-2022-0433","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial","volume":"18","author":"Smith","year":"2022","journal-title":"Future Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/10\/1248\/68694504\/hyag107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/10\/1248\/68694504\/hyag107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:07:13Z","timestamp":1791464833000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/10\/1248\/8724551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,7,3]]},"published-print":{"date-parts":[[2026,10,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag107","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,7,3]]}}}